Astellas Pharma’s Xtandi Gains Momentum in China with Positive Phase III ARCHES Study Results
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that its prostate cancer therapy, Xtandi (enzalutamide),...
Clinical trial results
CStone’s Ayvakit Shows Significant Improvements in ISM at AAAAI Meeting
China-based CStone Pharmaceuticals (HKG: 2616) announced that its US partner, Blueprint Medicines, published detailed data...
AusperBio Initiates Phase I Trial for AHB-137 in New Zealand
Sino-US liver therapy developer AusperBio has announced the initiation of the first cohort dosing in...
Inovio and ApolloBio Announce Positive Phase III Data for VGX-3100 Vaccine
US-based Inovio Pharmaceuticals (NASDAQ: INO) and China-based ApolloBio Corp. (NEEQ:430187) have announced positive data from...
Zhejiang Medicine’s ARX788 Shows Positive Results in Breast Cancer Study
China-based Zhejiang Medicine Co., Ltd (SHA: 600216) has announced positive results from a Phase II/III...
Junshi Biosciences’ PCSK9 Inhibitor Ongericimab Meets Phase III Endpoints
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that two randomized, double-blind, placebo-controlled, multi-center...
Zai Lab to Present Zejula OS Study Results at ESMO Congress
China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) is set to present two oral presentations...
Junshi Biosciences’ PD-1 Inhibitor Tuoyi Shows Promise in Phase III TNBC Study
Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced significant progress in the Phase...
Ascletis Pharma’s ASC10 Shows Promising Phase I Results at CROI 2023
China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive results from a Phase I clinical...
Junshi Biosciences and Coherus Report Positive JUPITER-02 Trial Results for NPC Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) and its US partner Coherus BioSciences...
Brii Biosciences Publishes Positive Phase II Results for HBV Treatment
China’s Brii Biosciences (HKG: 2137) has announced the publication of interim results from a Phase...
Kintor’s GT20029 Shows Positive Results in US Phase I Study for AGA and Acne
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced positive topline data from a Phase I...
OcuMension’s Phase I Study for Dry Eye Treatment OT-202 Concludes
Chinese ophthalmology specialist OcuMension Therapeutics (HKG: 1477) has announced the conclusion of a Phase I...
InnoCare’s Gunagratinib Shows Promising Data in Cholangiocarcinoma at ASCO-GI 2023
Beijing InnoCare Pharma Tech Co. (HKG: 9969), a China-based biotech specializing in cancer and autoimmune...
Legend Biotech’s Carvykti Meets Primary Endpoint in CARTITUDE-4 Phase III Study
Legend Biotech (NASDAQ: LEGN) has released positive data from the CARTITUDE-4 Phase III study, evaluating...
Hepagene’s FXR Agonist HPG1860 Shows Positive Phase IIa Data in NASH Study
China-based liver disease specialist Hepagene Therapeutics (HK) Limited has revealed positive data from the Phase...
Immunofoco’s CLDN18.2-Targeted CAR-T Therapy IMC002 Accepted for CDE Review
China’s Center for Drug Evaluation (CDE) has accepted a clinical trial filing for IMC002, an...
Keymed Biosciences’ CMG901 Shows Promising Results in Phase Ia Study for Solid Tumors
China-based Keymed Biosciences Inc. (HKG: 2162) has revealed the latest data update from a Phase...
Everest Medicines’ EVER206 Shows Positive Phase I Results in China
China-based Everest Medicines (HKG: 1952) has announced top-line results from a Phase I study in...
Junshi Biosciences’ Neotorch Study Achieves Superiority in Lung Cancer Trial
Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that its randomized, double-blind, placebo-controlled,...